Clinical utility of BRCA & HRD testing and interpretation of results
Speaker : Dr. Rajiv Sarin
Frequency and clinical significance of somatic and germline BRCA mutations
Speaker : Dr. Mithua Ghosh
Audit - Institutional BRCA data of 3 leading institutes by Dr. Amit Verma
Speaker : Dr. Amit Verma - Max Super Speciality Hospital, Saket, Delhi
Audit - Institutional BRCA data of 3 leading institutes by Dr. Rosina Ahmed
Speaker : Dr. Rosina Ahmed - Tata Medical Center, Kolkata
Audit - Institutional BRCA data of 3 leading institutes by Dr. Mithua Ghosh
Speaker : Dr. Mithua Ghosh - HCG, Banglore
Panel Discussion on clinical utility of BRCA testing
Moderator : Dr. Amit Verma
Debate - Observation versus maintenance therapy for recurrent ovarian cancer Pros and Cons
Speaker : Dr. Amit Agarwal vs Dr. Chetan Deshmukh
Moderator : Dr. Ramesh Nimmagadda
Panel Discussion on importance of platinum free interval in PSR ovarian cancer
Moderator : Dr. Ramesh Nimmagadda
Emerging data with PARPi as maintenance therapy for recurrent ovarian cancer
Speaker : Dr. Shaheenah Dawood
Debate : PARPi vs Angiogenesis inhibitors in maintenance treatment of recurrent ovarian cancer
Speaker : Dr. Bharat Bhosale vs Dr. Prasad Narayan
Moderator : Dr. Shona Nag
Panel Discussion on PARP inhibition and targeted therapy for ovarian cancer
Moderator : Dr. U D Bafna
Panel Discussion on Early HER2 positive breast cancer
Moderator : Dr. Shona Nag
Panel Discussion on metastatic HER2 positive breast cancer
Moderator : Dr. Seema Gulia
Understanding the moleculor heterogeneity of HER2 negative breast cancers
Debate : Every HR+ve MBC should receive CDK 4/6 inhibitors Yes/no?
Speaker : Dr. Amol Dongre vs Dr. Sandeep Batra
Moderator : Dr. D C Doval
Overview of platinums in metastatic Triple Negative Breast Cancer(TNBC)
Speaker : Dr. Anita Ramesh
Management of metastatic TNBC beyond 1st line therapy
Speaker : Dr. Joydeep Ghosh
PARP inhibitors in management of breast cancer
Speaker : Dr. Shaheenah Dawood